ArticleCancer2013

Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.

Shlomit Yust-Katz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.